Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz - FierceBiotech

* Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz  FierceBiotech * A new weight-loss drug dubbed the 'triple G' could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery  Yahoo Life * Eli Lilly (LLY) Weight-Loss Shot Gives Company's Strongest Results in Trial  Bloomberg * Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial  The Lancet * Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM  nejm.org * View Full Coverage on Google News
http://dlvr.it/SrHlZS